Revenko, Alexey S.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine

RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions

Cited by 445

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine

Protein Kinase Regulation and GTPase SignalingRNA Interference and Gene Delivery

Cited by 177

Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer’s disease

Baker, S. K., Chen, Z.-L., Norris, E. H., Revenko, A. S., MacLeod, A. R., & Strickland, S. (2018) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 68

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 20